SK287335B6 - Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov - Google Patents

Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov Download PDF

Info

Publication number
SK287335B6
SK287335B6 SK518-2003A SK5182003A SK287335B6 SK 287335 B6 SK287335 B6 SK 287335B6 SK 5182003 A SK5182003 A SK 5182003A SK 287335 B6 SK287335 B6 SK 287335B6
Authority
SK
Slovakia
Prior art keywords
treatment
formula
salt
methyl
pyrimidin
Prior art date
Application number
SK518-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5182003A3 (en
Inventor
Elisabeth Buchdunger
Renaud Capdeville
George Daniel Demetri
Sasa Dimitrijevic
Brian J. Druker
Jonathan A. Fletcher
Heikki Joensuu
Sandra Leta Silberman
David Tuveson
Michael C. Heinrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22920224&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287335(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK5182003A3 publication Critical patent/SK5182003A3/sk
Publication of SK287335B6 publication Critical patent/SK287335B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK518-2003A 2000-10-27 2001-10-26 Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov SK287335B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (2)

Publication Number Publication Date
SK5182003A3 SK5182003A3 (en) 2004-02-03
SK287335B6 true SK287335B6 (sk) 2010-07-07

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
SK518-2003A SK287335B6 (sk) 2000-10-27 2001-10-26 Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov

Country Status (26)

Country Link
US (1) US6958335B2 (hu)
EP (1) EP1332137B1 (hu)
JP (1) JP4386635B2 (hu)
KR (1) KR100885129B1 (hu)
CN (1) CN1276754C (hu)
AT (1) ATE321556T1 (hu)
AU (2) AU2002218262B2 (hu)
BR (1) BRPI0114870B8 (hu)
CA (1) CA2424470C (hu)
CY (1) CY1105055T1 (hu)
CZ (1) CZ303944B6 (hu)
DE (1) DE60118430T2 (hu)
DK (1) DK1332137T3 (hu)
ES (1) ES2260317T3 (hu)
HK (1) HK1058193A1 (hu)
HU (1) HU229106B1 (hu)
IL (2) IL155029A0 (hu)
MX (1) MXPA03003703A (hu)
NO (1) NO324948B1 (hu)
NZ (1) NZ525254A (hu)
PL (1) PL209733B1 (hu)
PT (1) PT1332137E (hu)
RU (1) RU2301066C2 (hu)
SK (1) SK287335B6 (hu)
WO (1) WO2002034727A2 (hu)
ZA (1) ZA200302155B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4477303B2 (ja) * 2001-05-16 2010-06-09 ノバルティス アーゲー Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミンおよび化学療法剤を含んでなる併用剤
PT1401416E (pt) * 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
WO2003002108A2 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
EP1401413B1 (en) * 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
CA2452366A1 (en) * 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
CA2452368A1 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20040242612A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
US20040242601A1 (en) * 2001-09-20 2004-12-02 Alain Moussy Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
ES2269994T3 (es) * 2002-02-27 2007-04-01 Ab Science Utilizacion de inhibidores de la tirosina quinasa, para el tratamiento de los trastornos del snc.
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
AU2004273605B2 (en) * 2003-09-19 2008-07-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
US20100210596A1 (en) * 2006-02-01 2010-08-19 Bluestone Jeffrey A Use of aminopyrimidine compounds in the treatment of immune disorders
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
WO2010120386A1 (en) 2009-04-17 2010-10-21 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
BR112013022552B1 (pt) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
CN102918029B (zh) 2011-05-17 2015-06-17 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
AU2013223749A1 (en) 2012-02-21 2014-09-11 Sun Pharmaceutical Industries Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US20140235631A1 (en) 2012-07-27 2014-08-21 Antonius Martinus Gustave Bunt Efflux inhibitor compositions and methods of treatment using the same
CA3172586A1 (en) 2013-07-31 2015-02-05 Avalyn Pharma Inc. Aerosol imatininb compounds and uses thereof
US11285152B2 (en) 2017-07-20 2022-03-29 Kashiv Biosciences, Llc Stable oral pharmaceutical composition of imatinib
CA3089566A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of gastrointestinal stromal tumors
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CN114615982A (zh) 2019-08-12 2022-06-10 德西费拉制药有限责任公司 用于治疗胃肠道间质瘤的瑞普替尼
CN115243681A (zh) 2019-12-30 2022-10-25 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
LT4084778T (lt) 2019-12-30 2024-01-25 Deciphera Pharmaceuticals, Llc Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (hu) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
EP1117397A1 (en) * 1998-08-31 2001-07-25 Sugen, Inc. Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity

Also Published As

Publication number Publication date
NZ525254A (en) 2006-02-24
HU229106B1 (en) 2013-07-29
NO324948B1 (no) 2008-01-07
NO20031833D0 (no) 2003-04-24
WO2002034727A3 (en) 2003-03-27
AU1826202A (en) 2002-05-06
IL155029A (en) 2009-09-22
JP4386635B2 (ja) 2009-12-16
HUP0301512A2 (hu) 2003-11-28
WO2002034727A2 (en) 2002-05-02
ZA200302155B (en) 2004-04-22
KR20030051656A (ko) 2003-06-25
CN1622808A (zh) 2005-06-01
DK1332137T3 (da) 2006-07-17
DE60118430D1 (de) 2006-05-18
DE60118430T2 (de) 2006-10-26
PT1332137E (pt) 2006-07-31
CN1276754C (zh) 2006-09-27
RU2301066C2 (ru) 2007-06-20
US6958335B2 (en) 2005-10-25
BRPI0114870B8 (pt) 2021-05-25
AU2002218262B2 (en) 2005-09-29
CA2424470A1 (en) 2002-05-02
EP1332137A2 (en) 2003-08-06
US20040023976A1 (en) 2004-02-05
CY1105055T1 (el) 2010-03-03
PL362148A1 (en) 2004-10-18
ATE321556T1 (de) 2006-04-15
CA2424470C (en) 2009-06-09
PL209733B1 (pl) 2011-10-31
CZ303944B6 (cs) 2013-07-10
CZ20031152A3 (en) 2004-04-14
BR0114870A (pt) 2004-02-17
JP2004512328A (ja) 2004-04-22
SK5182003A3 (en) 2004-02-03
ES2260317T3 (es) 2006-11-01
HK1058193A1 (en) 2004-05-07
IL155029A0 (en) 2003-10-31
NO20031833L (no) 2003-04-24
BRPI0114870B1 (pt) 2020-06-16
EP1332137B1 (en) 2006-03-29
KR100885129B1 (ko) 2009-02-23
MXPA03003703A (es) 2005-01-25

Similar Documents

Publication Publication Date Title
SK287335B6 (sk) Použitie 4-{(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyrid-3- yl)pyrimidin-2-ylamino]fenyl}-benzamidu na prípravu farmaceutických kompozícií na liečenie gastrointestinálnych strómových tumorov
AU2002218262A1 (en) Treatment of gastrointestinal stromal tumors
JP2016529245A (ja) 固形腫瘍の処置方法
JP2023058582A (ja) 神経芽細胞腫の治療における使用のためのオーロラａキナーゼ阻害剤
JP2022552880A (ja) 置換４－アミノイソインドリン－１，３－ジオン化合物および組合せ使用のための第２の活性剤
ES2934846T3 (es) Inhibidores de CDK para tratamiento de PAH
EP3976042A2 (en) Methods of treating cholangiocarcinoma
CN114728003A (zh) 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合
JP7333560B2 (ja) 放射線及び／又は化学療法の曝露に関連付けられる副作用を処置及び／又は防止する剤、組成物及びキット
EP1945272B1 (en) Method of scintigraphy
ES2935705T3 (es) Un ligando del receptor GABA A
US20190336621A1 (en) Radioactive compound for diagnosis of malignant melanoma and use thereof
SPIES et al. Vitamin B6 (Pyridoxin) Deficiency in Human Beings: Further Studies, with Special Emphasis on the Urinary Excretion of Pyridoxin
SG172922A1 (en) Combination therapies for neoplastic disorders
Herrera-Ornelas et al. Phase-I clinical trial of sodium cyanate in patients with advanced colorectal carcinoma
TW202126306A (zh) 嗜酸性球性病症之治療
CN117982507A (zh) 英菲格拉替尼在治疗胃癌和腺癌中的用途
CN117396202A (zh) 给药方案
JP2006507319A (ja) 中皮腫の処置

Legal Events

Date Code Title Description
PC4A Assignment and transfer of rights

Owner name: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., BOSTO, US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, , US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: NOVARTIS AG, BASEL, CH

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

Owner name: DANA-FARBER CANCER INSTITUTE INC., BOSTON, MA, US

Free format text: FORMER OWNER: NOVARTIS AG, BASEL, CH

Effective date: 20130917

QB4A Licence contract registered or granted

Free format text: NON-EXCLUSIVE LICENSE

Name of requester: NOVARTIS SLOVAKIA S.R.O., SK

Effective date: 20131031

MK4A Expiry of patent

Expiry date: 20211026